

# OFFICE OF FISCAL ANALYSIS

Legislative Office Building, Room 5200  
Hartford, CT 06106 ◊ (860) 240-0200  
<http://www.cga.ct.gov/ofa>

SB-13

## AN ACT REDUCING PRESCRIPTION DRUG PRICES. AMENDMENT

LCO No.: 4311

File Copy No.: 208

Senate Calendar No.: 164

---

### ***OFA Fiscal Note***

#### ***State Impact:***

Agency Affected	Fund-Effect	FY 23 \$	FY 24 \$
Department of Revenue Services	GF - Eliminates Revenue Gain in Bill	None	Potential
Department of Revenue Services	GF - Eliminates Potential Cost in Bill	Less than 500,000	Less than 500,000
State Comptroller - Fringe Benefits <sup>1</sup>	GF - Eliminates Potential Cost in Bill	Less than 202,650	Less than 202,650
Department of Revenue Services	GF - Eliminates Cost in Bill	None	Less than 100,000

Note: GF=General Fund

***Municipal Impact:*** None

#### ***Explanation***

The amendment, which strikes the provisions of the bill establishing the Covered Connecticut account and requiring pharmaceutical manufacturers that violate the bill's pricing provisions to annually pay the Department of Revenue Services (DRS) commissioner a civil

---

<sup>1</sup>The fringe benefit costs for most state employees are budgeted centrally in accounts administered by the Comptroller. The estimated active employee fringe benefit cost associated with most personnel changes is 40.53% of payroll in FY 23.

penalty, eliminates: 1) the potential revenue gain to the Covered Connecticut account beginning in FY 24, 2) the one-time cost to DRS of less than \$100,000 in FY 24, and 3) the potential cost to DRS of less than \$702,650 annually identified in the fiscal note on the underlying bill.

*The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely for the purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.*